Eli Lilly is the best of both worlds — a recession-resistant stock with major growth potential
The year ahead is pivotal for Eli Lilly (LLY) as the pharmaceutical giant advances its stellar drug pipeline.
Traders work beneath monitors displaying Eli Lilly signage on the floor of the New York Stock Exchange.
Michael Nagle | Bloomberg | Getty Images
The year ahead is pivotal for Eli Lilly (LLY) as the pharmaceutical giant looks to advance drugs in its stellar pipeline. Executives detailed reasons for optimism at a major industry gathering this week.